Keyphrases
A1 Receptor
100%
Agonism
25%
Co-agonist
100%
Disease Treatment
12%
Food Intake
25%
GLP-1 Receptor Agonist
37%
Glucagon
12%
Glucagon Receptor
100%
Glucagon-like
100%
Lifestyle Modification
12%
Lipid Peroxidation
12%
Liver Disease
12%
Liver Fibrosis
12%
Liver Inflammation
12%
Metabolic Syndrome
12%
Non-alcoholic Fatty Liver Disease (NAFLD)
100%
Novel Therapeutics
12%
Obesity
12%
Obesity Epidemic
12%
Pathophysiology
12%
Pharmacotherapy
12%
Receptor Agonist
100%
Receptor Signaling
12%
Reduction Effect
12%
Satiety
12%
Supraphysiological
12%
Targeted Treatment
12%
Thermogenesis
12%
Type 2 Diabetes Prevention
12%
Weight Loss
12%
Weight Reduction
12%
Western Countries
12%
Medicine and Dentistry
Body Weight
12%
Combination Therapy
12%
Drug Therapy
12%
Food Intake
25%
Glucagon
12%
Glucagon Like Peptide 1
100%
Glucagon Receptor
100%
Glucagon-Like Peptide-1 Agonist
100%
Hepatitis
12%
Lifestyle Modification
12%
Lipid Oxidation
12%
Liver Disease
12%
Liver Fibrosis
12%
Maturity Onset Diabetes of the Young
12%
Metabolic Syndrome
12%
Nonalcoholic Fatty Liver
100%
Pathophysiology
12%
Prevalence
12%
Satiety
12%
Thermogenesis
12%